Filing Flows

Filing Flows › 8-K events › Steris

Steris: entry into a material definitive agreement

Form 8-K filed Nov 4, 2026 · items 1.01, 1.02, 2.03

What the filing says

On November 4, 2026, STERIS plc (“STERIS”), STERIS Corporation (“Corporation”), STERIS Limited (“Limited”) and STERIS Irish FinCo Unlimited Company (“FinCo”), each as a borrower and guarantor, entered into a credit agreement (the “New Revolving Credit Agreement”) with various financial institutions and each of J.P. Mor

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,368. Item 2.03: 0.0% next session across 13,268. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Steris at a glance

Latest quarterQ2 FY27
Revenue$1.6B
Revenue Y/Y+9%
Operating margin18.5%
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies

Steris, Q2 FY27: revenue $1.6B (+9% year over year), operating margin 18.5%. The chart follows the revenue to costs, profit and cash.

Steris: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent debt and financing

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.